Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

The Faculty of Medicine - Immunology and Cancer Research: Aqeilan Rami


Last updated December 2021 -  Immunology and Cancer Research

List of Publications

(1) Repudi S, Kustanovich I, Abu-Swai S, Stern S, Aqeilan RI. Neonatal neuronal WWOX gene therapy rescues Wwox null phenotypes. EMBO Mol Med 2021;13(12).

(2) Breton VL, Aquilino MS, Repudi S, Saleem A, Mylvaganam S, Abu-Swai S, et al. Altered neocortical oscillations and cellular excitability in an in vitro Wwox knockout mouse model of epileptic encephalopathy. Neurobiol Dis 2021;160.

(3) MacHour FE, Abu-Zhayia ER, Awwad SW, Bidany-Mizrahi T, Meinke S, Bishara LA, et al. RBM6 splicing factor promotes homologous recombination repair of double-strand breaks and modulates sensitivity to chemotherapeutic drugs. Nucleic Acids Res 2021;49(20):11708-11727.

(4) Steinberg DJ, Aqeilan RI. Wwox-related neurodevelopmental disorders: Models and future perspectives. Cells 2021;10(11).

(5) Repudi S, Steinberg DJ, Elazar N, Breton VL, Aquilino MS, Saleem A, et al. Neuronal deletion of Wwox, associated with WOREE syndrome, causes epilepsy and myelin defects. Brain 2021;144(10):3061-3077.

(6) Sapir G, Steinberg DJ, Aqeilan RI, Katz-Brull R. Real-time non-invasive and direct determination of lactate dehydrogenase activity in cerebral organoids—a new method to characterize the metabolism of brain organoids? Pharmaceuticals 2021;14(9).

(7) Steinberg DJ, Repudi S, Saleem A, Kustanovich I, Viukov S, Abudiab B, et al. Modeling genetic epileptic encephalopathies using brain organoids. EMBO Mol Med 2021;13(8).

(8) Banne E, Abudiab B, Abu-Swai S, Repudi SR, Steinberg DJ, Shatleh D, et al. Neurological disorders associated with wwox germline mutations—a comprehensive overview. Cells 2021;10(4).

(9) Liebl MC, Moehlenbrink J, Becker H, Raddatz G, Abdeen SK, Aqeilan RI, et al. DAZAP2 acts as specifier of the p53 response to DNA damage. Nucleic Acids Res 2021;49(5):2759-2776.

(10) Aqeilan RI. Engineering organoids: a promising platform to understand biology and treat diseases. Cell Death Differ 2021;28(1).

(11) Yang X, Ma L, Wei R, Ye T, Zhou JK, Wen M, et al. Twist1-induced miR-199a-3p promotes liver fibrosis by suppressing caveolin-2 and activating TGF-β pathway. Signal Transduct Target Ther 2020;5(1).

(12) Khawaled S, Nigita G, Distefano R, Oster S, Suh S-, Smith Y, et al. Pleiotropic tumor suppressor functions of WWOX antagonize metastasis. Signal Transduct Target Ther 2020;5(1).

(13) Oster S, Aqeilan RI. Programmed DNA Damage and Physiological DSBs: Mapping, Biological Significance and Perturbations in Disease States. Cells 2020;9(8).

(14) Oster S, Aqeilan RI. Mapping the breakome reveals tight regulation on oncogenic super-enhancers. Mol Cell Oncol 2020;7(3).

(15) Maximov VV, Akkawi R, Khawaled S, Salah Z, Jaber L, Barhoum A, et al. MiR-16-1-3p and miR-16-2-3p possess strong tumor suppressive and antimetastatic properties in osteosarcoma. Int J Cancer 2019;145(11):3052-3063.

(16) Hazan I, Monin J, Bouwman BAM, Crosetto N, Aqeilan RI. Activation of Oncogenic Super-Enhancers Is Coupled with DNA Repair by RAD51. Cell Rep 2019;29(3):560-572.e4.

(17) Soudah T, Khawaled S, Aqeilan RI, Yavin E. AntimiR-155 Cyclic Peptide-PNA Conjugate: Synthesis, Cellular Uptake, and Biological Activity. ACS Omega 2019;4(9):13954-13961.

(18) Chang N-, Lin R, Sze C-, Aqeilan RI. Editorial: WW Domain Proteins in Signaling, Cancer Growth, Neural Diseases, and Metabolic Disorders. Front Oncol 2019;9.

(19) Abdeen SK, Aqeilan RI. Decoding the link between WWOX and p53 in aggressive breast cancer. Cell Cycle 2019;18(11):1177-1186.

(20) Salah Z, Melino G, Aqeilan RI. Correction: Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity (Cancer Research (2011) 71 (2010–2020) DOI: 10.1158/0008-5472.CAN-10-3516). Cancer Res 2019;79(11):3007.

(21) Khawaled S, Suh SS, Abdeen SK, Monin J, Distefano R, Nigita G, et al. WWOX inhibits metastasis of triple-negative breast cancer cells via modulation of miRNAs. Cancer Res 2019;79(8):1784-1798.

(22) Abu-Remaileh M, Abu-Remaileh M, Akkawi R, Knani I, Udi S, Pacold ME, et al. WWOX somatic ablation in skeletal muscles alters glucose metabolism. Mol Metab 2019;22:132-140.

(23) Druck T, Cheung DG, Park D, Trapasso F, Pichiorri F, Gaspari M, et al. Fhit–Fdxr interaction in the mitochondria: modulation of reactive oxygen species generation and apoptosis in cancer cells. Cell Death Dis 2019;10(3).

(24) Abu-Remaileh M, Khalaileh A, Pikarsky E, Aqeilan RI. Correction to: WWOX controls hepatic HIF1α to suppress hepatocyte proliferation and neoplasia (Cell Death & Disease, (2018), 9, 5, (511), 10.1038/s41419-018-0510-4). Cell Death Dis 2018;9(12).

(25) Peretz L, Besser E, Hajbi R, Casden N, Ziv D, Kronenberg N, et al. Combined shRNA over CRISPR/cas9 as a methodology to detect off-target effects and a potential compensatory mechanism. Sci Rep 2018;8(1).

(26) Gaudio E, Paduano F, Pinton S, D'Agostino S, Rocca R, Costa G, et al. TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line. Br J Haematol 2018;183(3):509-512.

(27) Tanna M, Aqeilan RI. Modeling WWOX loss of function in vivo: What have we learned? Front Oncol 2018;8(OCT).

(28) Gershkovitz M, Fainsod-Levi T, Khawaled S, Shaul ME, Sionov RV, Cohen-Daniel L, et al. Microenvironmental cues determine tumor cell susceptibility to neutrophil cytotoxicity. Cancer Res 2018;78(17):5050-5059.

(29) Abdeen SK, Ben-David U, Shweiki A, Maly B, Aqeilan RI. Somatic loss of WWOX is associated with TP53 perturbation in basal-like breast cancer. Cell Death Dis 2018;9(8).

(30) Ma L, Yang X, Wei R, Ye T, Zhou J-, Wen M, et al. MicroRNA-214 promotes hepatic stellate cell activation and liver fibrosis by suppressing Sufu expression article. Cell Death Dis 2018;9(7).

(31) Gershkovitz M, Caspi Y, Fainsod-Levi T, Katz B, Michaeli J, Khawaled S, et al. TRPM2 mediates neutrophil killing of disseminated tumor cells. Cancer Res 2018;78(10):2680-2690.

(32) Abu-Remaileh M, Khalaileh A, Pikarsky E, Aqeilan RI. WWOX controls hepatic HIF1α to suppress hepatocyte proliferation and neoplasia article. Cell Death Dis 2018;9(5).

(33) Trapasso F, Pichiorri F, Gaspari M, Palumbo T, Aqeilan RI, Gaudio E, et al. Retraction: Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells (The Journal of biological chemistry (2008) 283 20 (13736-13744)). J Biol Chem 2017;292(34):14279.

(34) Khawaled S, Aqeilan RI. RUNX1, a new regulator of EMT in breast cancer. Oncotarget 2017;8(11):17407-17408.

(35) Hazan I, Hofmann TG, Aqeilan RI. Tumor Suppressor Genes within Common Fragile Sites Are Active Players in the DNA Damage Response. PLoS Genet 2016;12(12).

(36) Del Mare S, Husanie H, Iancu O, Abu-Odeh M, Evangelou K, Lovat F, et al. WWOX and p53 dysregulation synergize to drive the development of osteosarcoma. Cancer Res 2016;76(20):6107-6117.

(37) Pichiorri F, Suh S-, Rocci A, De Luca L, Taccioli C, Santhanam R, et al. Erratum: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development (Cancer Cell (2010) 18(4) (367–381) (S1535610810003429) (10.1016/j.ccr.2010.09.005)). Cancer Cell 2016;30(2):349-351.

(38) Maximov VV, Aqeilan RI. Genetic factors conferring metastasis in osteosarcoma. Future Oncol 2016;12(13):1623-1644.

(39) Gaudio E, Paduano F, Ngankeu A, Ortuso F, Lovat F, Pinton S, et al. A Fhit-mimetic peptide suppresses annexin A4-mediated chemoresistance to paclitaxel in lung cancer cells. Oncotarget 2016;7(21):29927-29936.

(40) Abu-Odeh M, Hereema NA, Aqeilan RI. WWOX modulates the ATR-mediated DNA damage checkpoint response. Oncotarget 2016;7(4):4344-4355.

(41) Abu-Remaileh M, Joy-Dodson E, Schueler-Furman O, Aqeilan RI. Pleiotropic functions of tumor suppressor WWOX in normal and cancer cells. J Biol Chem 2015;290(52):30728-30735.

(42) Hazan I, Aqeilan R. Current questions and controversies in chromosome fragile site research: does WWOX, the gene product of common fragile site FRA16D, have a passive or active role in cancer? Cell Death Discov 2015;1(1).

(43) Hazan I, Abu-Odeh M, Hofmann TG, Aqeilan RI. WWOX guards genome stability by activating ATM. Mol Cell Oncol 2015;2(4).

(44) Del Mare S, Aqeilan RI. Tumor Suppressor WWOX inhibits osteosarcoma metastasis by modulating RUNX2 function. Sci Rep 2015;5.

(45) Abu-Remaileh M, Seewaldt VL, Aqeilan RI. WWOX loss activates aerobic glycolysis. Mol Cell Oncol 2015;2(2).

(46) Abu-Remaileh M, Aqeilan RI. The tumor suppressor WW domain-containing oxidoreductase modulates cell metabolism. Exp Biol Med 2015;240(3):345-350.

(47) Alian A, Aqeilan RI. Comment on: Melino S, et al. p63 threonine phosphorylation signals the interaction with the WW domain of the E3 ligase Itch. Cell Cycle 2014; 13(20):3207-17; http:.// Cell Cycle 2015;14(4):469-470.

(48) Salah Z, Arafeh R, Maximov V, Galasso M, Khawaled S, Abou-Sharieha S, et al. miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cells. Oncotarget 2015;6(7):4920-4935.

(49) Abu-Odeh M, Salah Z, Herbel C, Hofmann TG, Aqeilan RI. WWOX, the common fragile site FRA16D gene product, regulates ATM activation and the DNA damage response. Proc Natl Acad Sci U S A 2014;111(44):E4716-E4725.

(50) Abu-Remaileh M, Aqeilan RI. Tumor suppressor WWOX regulates glucose metabolism via HIF1α modulation. Cell Death Differ 2014;21(11):1805-1814.

(51) Gordon JAR, Montecino MA, Aqeilan RI, Stein JL, Stein GS, Lian JB. Epigenetic pathways regulating bone homeostasis:Potential targeting for intervention of skeletal disorders. Curr Osteoporosis Rep 2014;12(4):496-506.

(52) Aqeilan RI, Abu-Remaileh M, Abu-Odeh M. The common fragile site FRA16D gene product WWOX: Roles in tumor suppression and genomic stability. Cell Mol Life Sci 2014;71(23):4589-4599.

(53) Suh S-, Yoo JY, Cui R, Kaur B, Huebner K, Lee T-, et al. FHIT Suppresses Epithelial-Mesenchymal Transition (EMT) and Metastasis in Lung Cancer through Modulation of MicroRNAs. PLoS Genet 2014;10(10).

(54) Iatan I, Choi HY, Ruel I, Linga Reddy MVP, Kil H, Lee J, et al. The WWOX gene modulates high-density lipoprotein and lipid metabolism. Circ Cardiovasc Genet 2014;7(4):491-504.

(55) Abu-Odeh M, Bar-Mag T, Huang H, Kim T, Salah Z, Abdeen SK, et al. Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks. J Biol Chem 2014;289(13):8865-8880.

(56) Aqeilan RI. Role of common fragile sites and corresponding genes in cancer development. Cell Mol Life Sci 2014;71(23):4487-4488.

(57) Salah Z, Itzhaki E, Aqeilan RI. The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway. Oncotarget 2014;5(21):10886-10900.

(58) Gardenswartz A, Aqeilan RI. WW domain-containing oxidoreductase's role in myriad cancers: Clinical significance and future implications. Exp Biol Med 2014;239(3):253-263.

(59) Salah Z, Cohen S, Itzhaki E, Aqeilan RI. NEDD4 E3 ligase inhibits the activity of the Hippo pathway by targeting LATS1 for degradation. Cell Cycle 2013;12(24):3817-3823.

(60) Gaudio E, Paduano F, Spizzo R, Ngankeu A, Zanesi N, Gaspari M, et al. Fhit delocalizes Annexin A4 from plasma membrane to cytosol and sensitizes lung cancer cells to paclitaxel. PLoS ONE 2013;8(11).

(61) Aqeilan RI. Hippo signaling: To die or not to die. Cell Death Differ 2013;20(10):1287-1288.

(62) Abdeen SK, Del Mare S, Hussain S, Abu-Remaileh M, Salah Z, Hagan J, et al. Conditional inactivation of the mouse Wwox tumor suppressor gene recapitulates the null phenotype. J Cell Physiol 2013;228(7):1377-1382.

(63) Abdeen SK, Salah Z, Khawaled S, Aqeilan RI. Characterization of WWOX inactivation in murine mammary gland development. J Cell Physiol 2013;228(7):1391-1396.

(64) Gaudio E, Paduano F, Ngankeu A, Lovat F, Fabbri M, Sun H-, et al. Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas. Blood 2013;121(2):351-359.

(65) Salah Z, Bar-mag T, Kohn Y, Pichiorri F, Palumbo T, Melino G, et al. Tumor suppressor WWOX binds to ΔNp63α and sensitizes cancer cells to chemotherapy. Cell Death Dis 2013;4.

(66) McDonald CB, Buffa L, Bar-Mag T, Salah Z, Bhat V, Mikles DC, et al. Biophysical basis of the binding of WWOX tumor suppressor to WBP1 and WBP2 adaptors. J Mol Biol 2012;422(1):58-74.

(67) Sundvall M, Korhonen A, Vaparanta K, Anckar J, Halkilahti K, Salah Z, et al. Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein. J Biol Chem 2012;287(27):23216-23226.

(68) Suh S-, Yoo JY, Nuovo GJ, Jeon Y-, Kim S, Lee TJ, et al. MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci U S A 2012;109(14):5316-5321.

(69) Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, et al. miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res 2012;72(7):1865-1877.

(70) Gaudio E, Spizzo R, Paduano F, Luo Z, Efanov A, Palamarchuk A, et al. Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies. Blood 2012;119(1):180-187.

(71) Salah Z, Alian A, Aqeilan RI. WW domain-containing proteins: Retrospectives and the future. Front Biosci 2012;17(1):331-348.

(72) Pichiorri F, De Luca L, Aqeilan RI. Micrornas: New players in multiple myeloma. Front Genet 2011;2(MAY).

(73) Abdeen SK, Salah Z, Maly B, Smith Y, Tufail R, Abu-Odeh M, et al. Wwox inactivation enhances mammary tumorigenesis. Oncogene 2011;30(36):3900-3906.

(74) Salah Z, Aqeilan RI. WW domain interactions regulate the Hippo tumor suppressor pathway. Cell Death Dis 2011;2(6).

(75) Zanesi N, Drusco A, Pekarsky Y, Costinean S, Antenucci A, Conti L, et al. Common fragile site tumor suppressor genes and corresponding mouse models of cancer. J Biomed Biotechnol 2011;2011.

(76) Salah Z, Melino G, Aqeilan RI. Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity. Cancer Res 2011;71(5):2010-2020.

(77) Fu J, Qu Z, Yan P, Ishikawa C, Aqeilan RI, Rabson AB, et al. The tumor suppressor gene WWOX links the canonical and noncanonical NF-κB pathways in HTLV-I Tax-mediated tumorigenesis. Blood 2011;117(5):1652-1661.

(78) Sundvall M, Veikkolainen V, Kurppa K, Salah Z, Tvorogov D, Van Zoelen EJ, et al. Cell death or survival promoted by alternative isoforms of ErbB4. Mol Biol Cell 2010;21(23):4275-4286.

(79) Pichiorri F, Suh S-, Rocci A, De Luca L, Taccioli C, Santhanam R, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010;18(4):367-381.

(80) Kurek KC, Del Mare S, Salah Z, Abdeen S, Sadiq H, Lee S-, et al. Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. Cancer Res 2010;70(13):5577-5586.

(81) Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Res 2010;20(5):589-599.

(82) Aqeilan RI, Calin GA, Croce CM. MiR-15a and miR-16-1 in cancer: Discovery, function and future perspectives. Cell Death Differ 2010;17(2):215-220.

(83) Salah Z, Aqeilan R, Huebner K. WWOX gene and gene product: tumor suppression through specific protein interactions. Future Oncol 2010;6(2):249-259.

(84) Del Mare S, Salah Z, Aqeilan RI. WWOX: Its genomics, partners, and functions. J Cell Biochem 2009;108(4):737-745.

(85) Li Z, Hassan MQ, Jafferji M, Aqeilan RI, Garzon R, Croce CM, et al. Erratum: Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation (Journal of Biological Chemistryc(2009)284(15676–15684)Doi:10.1074/jbc.M809787200). J Biol Chem 2009;294(25):10018.

(86) Li Z, Hassan MQ, Jafferji M, Aqeilan RI, Garzon R, Croce CM, et al. Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem 2009;284(23):15676-15684.

(87) Trapasso F, Aqeilan RI, Iuliano R, Visone R, Gaudio E, Ciuffini L, et al. Targeted disruption of the murine homeodomain-interacting protein kinase-2 causes growth deficiency in vivo and cell cycle arrest in vitro. DNA Cell Biol 2009;28(4):161-167.

(88) Aqeilan RI, Hagan JP, De Bruin A, Rawahneh M, Salah Z, Gaudio E, et al. Targeted ablation of the WW domain-containing oxidoreductase tumor suppressor leads to impaired steroidogenesis. Endocrinology 2009;150(3):1530-1535.

(89) Pichiorri F, Suh S-, Ladetto M, Kuehl M, Palumbo T, Drandi D, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A 2008;105(35):12885-12890.

(90) Lee JC, Weissglas-Volkov D, Kyttälä M, Dastani Z, Cantor RM, Sobel EM, et al. WW-Domain-Containing Oxidoreductase Is Associated with Low Plasma HDL-C Levels. Am J Hum Genet 2008;83(2):180-192.

(91) Aqeilan RI, Hassan MQ, De Bruin A, Hagan JP, Volinia S, Palumbo T, et al. The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism. J Biol Chem 2008;283(31):21629-21639.

(92) Melino G, Gallagher E, Aqeilan RI, Knight R, Peschiaroli A, Rossi M, et al. Itch: A HECT-type E3 ligase regulating immunity, skin and cancer. Cell Death Differ 2008;15(7):1103-1112.

(93) Nakayama S, Semba S, Maeda N, Aqeilan RI, Huebner K, Yokozaki H. Role of the WWOX gene, encompassing fragile region FRA16D, in suppression of pancreatic carcinoma cells. Cancer Sci 2008;99(7):1370-1376.

(94) Trapasso F, Pichiorri F, Gaspari M, Palumbo T, Aqeilan RI, Gaudio E, et al. Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells. J Biol Chem 2008;283(20):13736-13744.

(95) Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A 2008;105(13):5166-5171.

(96) Aqeilan RI, Zanesi N, Croce CM. Environmental, Genetic, and Viral Causes of Cancer. The Biology and Treatment of Cancer: Understanding Cancer; 2008. p. 35-56.

(97) Sundvall M, Korhonen A, Paatero I, Gaudio E, Melino G, Croce CM, et al. Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proc Natl Acad Sci U S A 2008;105(11):4162-4167.

(98) Aqeilan RI, Donati V, Gaudio E, Nicoloso MS, Sundvall M, Korhonen A, et al. Association of Wwox with ErbB4 in breast cancer. Cancer Res 2007;67(19):9330-9336.

(99) Aqeilan RI, Croce CM. WWOX in biological control and tumorigenesis. J Cell Physiol 2007;212(2):307-310.

(100) Oberst A, Malatesta M, Aqeilan RI, Rossi M, Salomoni P, Murillas R, et al. The Nedd4-binding partner 1 (N4BP1) protein is an inhibitor of the E3 ligase Itch. Proc Natl Acad Sci U S A 2007;104(27):11280-11285.

(101) Sayan BS, Sayan AE, Ai LY, Aqeilan RI, Candi E, Cohen GM, et al. Cleavage of the transactivation-inhibitory domain of p63 by caspases enhances apoptosis. Proc Natl Acad Sci U S A 2007;104(26):10871-10876.

(102) Aqeilan RI, Hagan JP, Aqeilan HA, Pichiorri F, Fong LYY, Croce CM. Inactivation of the Wwox gene accelerates forestomach tumor progression in vivo. Cancer Res 2007;67(12):5606-5610.

(103) Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A, et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007;26(28):4148-4157.

(104) Pekarsky Y, Zanesi N, Aqeilan RI, Croce CM. Animal models for chronic lymphocytic leukemia. J Cell Biochem 2007;100(5):1109-1118.

(105) Aqeilan RI, Trapasso F, Hussain S, Costinean S, Marshall D, Pekarsky Y, et al. Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci U S A 2007;104(10):3949-3954.

(106) Donati V, Fontanini G, Dell'Omodarme M, Prati MC, Nuti S, Lucchi M, et al. WWOX expression in different histologic types and subtypes of non-small cell lung cancer. Clin Cancer Res 2007;13(3):884-891.

(107) Gaudio E, Palamarchuk A, Palumbo T, Trapasso F, Pekarsky Y, Croce CM, et al. Physical association with WWOX suppresses c-Jun transcriptional activity. Cancer Res 2006;66(24):11585-11589.

(108) Rossi M, Aqeilan RI, Neale M, Candi E, Salomoni P, Knight RA, et al. The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc Natl Acad Sci U S A 2006;103(34):12753-12758.

(109) Palamarchuk A, Zanesi N, Aqeilan RI, Efanov A, Maximov V, Santanam U, et al. Tal1 transgenic expression reveals absence of B lymphocytes. Cancer Res 2006;66(12):6014-6017.

(110) Trapasso F, Drusco A, Costinean S, Alder H, Aqeilan RI, Iuliano R, et al. Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis. DNA Cell Biol 2006;25(6):376-382.

(111) Pichiorri F, Trapasso F, Palumbo T, Aqeilan RI, Drusco A, Blaser BW, et al. Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35. Clin Cancer Res 2006;12(11 I):3494-3501.

(112) Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, et al. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A 2006;103(13):5078-5083.

(113) Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. Erratum: miR-15 and miR-16 induce apoptosis by targeting BCL2 (Proceedings of the National Academy of Sciences of the United States of America (September 27, 2005) 102, 39 (13944-13949) DOI: 10.1073/pnas.0506654102). Proc Natl Acad Sci U S A 2006;103(7):2464.

(114) Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, Pekarsky Y. Akt phosphorylates and regulates Pdcd4 tumor suppressor protein. Cancer Res 2005;65(24):11282-11286.

(115) Fabbri M, Iliopoulos D, Trapasso F, Aqeilan RI, Cimmino A, Zanesi N, et al. WWOX gene restoration prevents lung cancer growth in vitro and in vitro. Proc Natl Acad Sci U S A 2005;102(43):15611-15616.

(116) Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005;102(39):13944-13949.

(117) Aqeilan RI, Donati V, Palamarchuk A, Trapasso F, Kaou M, Pekarsky Y, et al. WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res 2005;65(15):6764-6772.

(118) Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, Pekarsky Y. Akt phosphorylates Tal1 oncoprotein and inhibits its represser activity. Cancer Res 2005;65(11):4515-4519.

(119) Sarti M, Sevignani C, Calin GA, Aqeilan R, Shimizu M, Pentimalli F, et al. Adenoviral transduction of TESTIN gene into breast and uterine cancer cell lines promotes apoptosis and tumor reduction in vivo. Clin Cancer Res 2005;11(2 I):806-813.

(120) Pekarsky Y, Calin GA, Aqeilan R, Croce CM. Chronic lymphocytic leukemia: Molecular genetics and animal models. Curr Top Microbiol Immunol 2005;294:51-70.

(121) Aqeilan RI, Palamarchuk A, Weigel RJ, Herrero JJ, Pekarsky Y, Croce CM. Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2γ transcription factor. Cancer Res 2004;64(22):8256-8261.

(122) Trapasso F, Sarti M, Cesari R, Yendamuri S, Dumon KR, Aqeilan RI, et al. Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models. Cancer Gene Ther 2004;11(9):633-641.

(123) Pekarsky Y, Zanesi N, Aqeilan R, Croce CM. Tcl1 as a model for lymphomagenesis. Hematol Oncol Clin North Am 2004;18(4):863-879.

(124) Aqeilan RI, Kuroki T, Pekarsky Y, Albagha O, Trapasso F, Baffa R, et al. Loss of WWOX Expression in Gastric Carcinoma. Clin Cancer Res 2004;10(9):3053-3058.

(125) Kuroki T, Yendamuri S, Trapasso F, Matsuyama A, Aqeilan RI, Alder H, et al. The Tumor Suppressor Gene WWOX at FRA16D Is Involved in Pancreatic Carcinogenesis. Clin Cancer Res 2004;10(7):2459-2465.

(126) Aqeilan RI, Pekarsky Y, Herrero JJ, Palamarchuk A, Letofsky J, Druck T, et al. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci U S A 2004;101(13):4401-4406.

(127) Pekarsky Y, Garrison PN, Palamarchuk A, Zanesi N, Aqeilan RI, Huebner K, et al. Fhit is a physiological target of the protein kinase Src. Proc Natl Acad Sci U S A 2004;101(11):3775-3779.

(128) Ben-Yehudah A, Aqeilan R, Robashkevich D, Lorberboum-Galski H. Using apoptosis for targeted cancer therapy by a new gonadotropin releasing hormone-DNA fragmentation factor 40 chimeric protein. Clin Cancer Res 2003;9(3):1179-1190.

(129) Aqeilan R, Kedar R, Ben-Yehudah A, Lorberboum-Galski H. Mechanism of action of interleukin-2 (IL-2)-Bax, an apoptosis-inducing chimaeric protein targeted against cells expressing the IL-2 receptor. Biochem J 2003;370(1):129-140.

(130) Ben-Yehudah A, Belostotsky R, Lichtenstein M, Aqeilan R, Abady R, Lorberboum-Galski H. Chimeric proteins as candidates for cancer treatment. Drugs Future 2002;27(9):851-861.

(131) Ben-Yehudah A, Aqeilan R, Belostotsky R, Azar Y, Lorberboum-Galski H. Utilizing chimeric proteins for exploring the cellular fate of endogenous proteins. Biochem Biophys Res Commun 2002;290(1):332-338.

(132) Aqeilan R, Yarkoni S, Lorberboum-Galski H. Interleukin 2-Bax: A novel prototype of human chimeric proteins for targeted therapy. FEBS Lett 1999;457(2):271-276.